Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer

Breast Cancer, Metastatic Breast Cancer Clinical Trial

Official title: Safety of Herceptin in Metastatic Breast Cancer

Status Completed

Clinical Trial Summary

This study was designed to evaluate safety and tolerability of Herceptin as treatment for patients with human epidermal growth factor receptor 2 (HER-2) positive metastatic breast cancer. Frequency, characteristics and severity of adverse events (AE) and serious adverse events (SAE) were followed to evaluate the safety of Herceptin in patients with HER2 positive metastatic breast cancer.

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Breast Cancer, Metastatic Breast Cancer
• Breast Neoplasms

• NCT number: NCT02424682
• Study type: Observational
• Source: Hoffmann-La Roche
• Status: Completed
• Phase: N/A
• Start date: August 2007
• Completion date: May 2009